1354722-74-9
Chemical Structure
Lysophosphatidylethanolamine (20:5)
Synonym(s): LysoPE(0:0/20:5)
- CAS No.: 1354722-74-9
- Formula:C25H42NO7P
- Molecular Weight:499.58
InChIKey: KCWGBXXAJHVZNN-KOYQJJOGSA-N
SMILES: [H][C@@](COC(CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)(COP(O)(OCCN)=O)O
Biological Activity: Lysophosphatidylethanolamine (20:5) (LysoPE (0:0/20:5)) is a lysophosphatidylethanolamine containing a 20:5 acyl chain. Lysophosphatidylethanolamine (20:5) competitively binds to site 1 and site 2 of human serum albumin (HSA), with Ki values of 13.77 μM and 4.02 μM, respectively. Lysophosphatidylethanolamine (20:5) is elevated in Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity and is reduced by BP1. Lysophosphatidylethanolamine (20:5) is useful for metabolomics and biomarker studies of cardiomyopathy, type 2 diabetes insulin resistance, and obesity[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lysophosphatidylethanolamine (20:5) | Lysophosphatidylethanolamine (20:5) (LysoPE (0:0/20:5)) is a lysophosphatidylethanolamine containing a 20:5 acyl chain. Lysophosphatidylethanolamine (20:5) competitively binds to site 1 and site 2 of human serum albumin (HSA), with Ki values of 13.77 μM and 4.02 μM, respectively. Lysophosphatidylethanolamine (20:5) is elevated in Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity and is reduced by BP1. Lysophosphatidylethanolamine (20:5) is useful for metabolomics and biomarker studies of cardiomyopathy, type 2 diabetes insulin resistance, and obesity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Thakur S, et al. Multiomics Analysis Reveals the Protective Effect of a Novel Bioactive Peptide (BP1) in Cardiomyopathy Using a Zebrafish Model. Journal of proteome research. 2026 May 01;25(5):2279-2295.
- [2]. Diamanti K, et al. Integration of whole-body [F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes. Scientific reports. 2020 May 20;10(1):8343.
- [3]. Inoue N, et al. Profiling of lysophosphatidylethanolamine molecular species in human serum and in silico prediction of the binding site on albumin. BioFactors (Oxford, England). 2022 Sep;48(5):1076-1088.
- [4]. Kim HY, et al. Lysophospholipid profile in serum and liver by high-fat diet and tumor induction in obesity-resistant BALB/c mice. Nutrition (Burbank, Los Angeles County, Calif.). 2014;30(11-12):1433-41.
